Arrowhead reports early data for dual-gene RNAi therapy ARO-DIMER-PA
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Nasdaq leads Wall Street lower on AI spending jitters; oil prices rebound
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
Arrowhead Pharmaceuticals Announces Interim Topline Clinical Data for the First Dual-Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia
September 15, 2026 7:30 AM EDT- ARO-DIMER-PA achieved deep and durable silencing of two genes with a single RNAi molecule
- Mean maximal single dose reductions in serum PCSK9 of 72% and APOC3 of 88%
- Clinical validation further demonstrates Arrowheads position as the leading innovator in siRNA therapies -
PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals,... More



